Ferric Carboxymaltose Therapy

Magnitude of Ferritin Increase

The American College of Hematology recommends ferric carboxymaltose for patients with iron deficiency anemia, resulting in a mean ferritin increase of 264 ng/mL from baseline levels, demonstrating robust storage replenishment in patients with sufficient baseline ferritin levels 1, 2
The European Society of Hematology notes that cancer-related anemia patients experience a mean ferritin increase of 1,200 ng/mL from a baseline of 190 ng/mL after a cumulative dose of 1,100 mg over 16 weeks 1, 2

The European Journal of Heart Failure suggests that a maximum single dose of 1,000 mg iron administered over a minimum of 15 minutes produces a dose-dependent ferritin response, with higher cumulative doses resulting in greater storage replenishment 3
The European Society of Cardiology recommends reassessing iron status 3 months after initial treatment, as ferritin levels cannot be used as an accurate indicator of iron status within 4 weeks of IV iron administration due to acute-phase reactant effects 3

The American Heart Association advises that for chronic conditions like heart failure, routine iron status evaluation should be considered 1-2 times per year, and ferritin levels should not be used as an indicator of iron status within 4 weeks of IV iron administration 3, 5
The World Journal of Emergency Surgery reports that a single dose of 1,000 mg ferric carboxymaltose produces a mean hemoglobin increase of 8 g/L over 8 days, with reticulocytosis occurring at 3-5 days after administration, indicating active erythropoiesis 6
The American College of Gastroenterology notes that in inflammatory conditions, such as IBD, cancer, and heart failure, hepcidin activation impairs oral iron absorption, making IV ferric carboxymaltose particularly effective at overcoming this barrier 6, 4